Ethypharm acquires Mesalazine suppository form from Jiangsu Anbison Pharmaceutical to expand its portfolio in China

Jun 13, 2024•about 1 year ago

Acquiring Company

Ethypharm

Acquired Company

Jiangsu Anbison Pharmaceutical

Saint Cloud

ShanghaiHealth CarePharmaceuticalBiotechnologyHealth Care

Description

Ethypharm, a leading pharmaceutical company, has successfully acquired the suppository form of Mesalazine from Jiangsu Anbison Pharmaceutical. This strategic move aims to expand Ethypharm's portfolio in China, allowing the company to better meet the demand for quality treatments and reinforcing its position in the Chinese market.

Company Information

Company

Ethypharm

Location

Saint Cloud, Minnesota, United States

About

Ethypharm is a European pharmaceutical company focused on the Central Nervous System and Critical Care treatments. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible.

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor

M&A deals with strong technology integration plans are 2.5x more likely to succeed

Related People

Ethypharm acquires Mesalazine suppository form from Jiangsu Anbison Pharmaceutical to expand its portfolio in China

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

M&A Insights

Related People

Éric hidden

Denis hidden

Xavier hidden

Company Information